Most Popular
1. Banking Crisis is Stocks Bull Market Buying Opportunity - Nadeem_Walayat
2.The Crypto Signal for the Precious Metals Market - P_Radomski_CFA
3. One Possible Outcome to a New World Order - Raymond_Matison
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
5. Apple AAPL Stock Trend and Earnings Analysis - Nadeem_Walayat
6.AI, Stocks, and Gold Stocks – Connected After All - P_Radomski_CFA
7.Stock Market CHEAT SHEET - - Nadeem_Walayat
8.US Debt Ceiling Crisis Smoke and Mirrors Circus - Nadeem_Walayat
9.Silver Price May Explode - Avi_Gilburt
10.More US Banks Could Collapse -- A Lot More- EWI
Last 7 days
Stock Market Volatility (VIX) - 25th Mar 24
Stock Market Investor Sentiment - 25th Mar 24
The Federal Reserve Didn't Do Anything But It Had Plenty to Say - 25th Mar 24
Stock Market Breadth - 24th Mar 24
Stock Market Margin Debt Indicator - 24th Mar 24
It’s Easy to Scream Stocks Bubble! - 24th Mar 24
Stocks: What to Make of All This Insider Selling- 24th Mar 24
Money Supply Continues To Fall, Economy Worsens – Investors Don’t Care - 24th Mar 24
Get an Edge in the Crypto Market with Order Flow - 24th Mar 24
US Presidential Election Cycle and Recessions - 18th Mar 24
US Recession Already Happened in 2022! - 18th Mar 24
AI can now remember everything you say - 18th Mar 24
Bitcoin Crypto Mania 2024 - MicroStrategy MSTR Blow off Top! - 14th Mar 24
Bitcoin Gravy Train Trend Forecast 2024 - 11th Mar 24
Gold and the Long-Term Inflation Cycle - 11th Mar 24
Fed’s Next Intertest Rate Move might not align with popular consensus - 11th Mar 24
Two Reasons The Fed Manipulates Interest Rates - 11th Mar 24
US Dollar Trend 2024 - 9th Mar 2024
The Bond Trade and Interest Rates - 9th Mar 2024
Investors Don’t Believe the Gold Rally, Still Prefer General Stocks - 9th Mar 2024
Paper Gold Vs. Real Gold: It's Important to Know the Difference - 9th Mar 2024
Stocks: What This "Record Extreme" Indicator May Be Signaling - 9th Mar 2024
My 3 Favorite Trade Setups - Elliott Wave Course - 9th Mar 2024
Bitcoin Crypto Bubble Mania! - 4th Mar 2024
US Interest Rates - When WIll the Fed Pivot - 1st Mar 2024
S&P Stock Market Real Earnings Yield - 29th Feb 2024
US Unemployment is a Fake Statistic - 29th Feb 2024
U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - 29th Feb 2024
What a Breakdown in Silver Mining Stocks! What an Opportunity! - 29th Feb 2024
Why AI will Soon become SA - Synthetic Intelligence - The Machine Learning Megatrend - 29th Feb 2024
Keep Calm and Carry on Buying Quantum AI Tech Stocks - 19th Feb 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Biotech Long-Term Profit Machines Stock Prices on Sale

Companies / BioTech Apr 25, 2014 - 12:25 PM GMT

By: Money_Morning

Companies

Michael A. Robinson writes: Market volatility has suddenly created some great opportunities, including those in the biotech sector.

Supporting the inevitable ascent of the industry is the release of a steady stream of compounds that have helped them rack up billions in new revenue.

Consider that since it began trading in early 2001, the iShares Nasdaq Biotechnology Index (Nasdaq: IBB) is up 130%. That's more than triple the S&P 500's 13-year return of 43%.


And for biotech as a group, things just keep getting better, with a number of leaders crushing the market over the last two years.

One example is Gilead Sciences Inc. (Nasdaq: GILD), which has returned roughly 185% in two years. Gilead has treatments for HIV, cardiovascular diseases, hepatitis C, and more.

Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) has a two-year return of 187%. The company is best known for EYELEA, a compound that combats age-related macular degeneration of the eyes that can lead to blindness.

But as impressive as these stocks have been, there are three great opportunities in the sector with just as much, if not more, potential that just got cheap.

They're all 2014 IPOs... and the market hasn't quite figured out just how profitable they'll be.

For the time being, these shares are in the discount bin. They won't stay there for long...

Profit Machine No. 1

Auspex Pharmaceuticals

Auspex Pharmaceuticals Inc. (Nasdaq: ASPX) went public on Feb. 5 with an offering price of $12. It was recently trading at $23 for gains to date of 92%.

Auspex specializes in developing drugs to treat orphan diseases, defined as those that affect fewer than 200,000 patients. Because there are more than 6,000 such diseases in the United States, the federal government gives firms what amounts to a 7-year monopoly on orphan drugs.

Based in suburban San Diego, Auspex is focused on conditions that cause hyperkinetic movement disorders such as Huntington's disease and Tourette's syndrome.

It's most promising candidate is SD-809, a drug proposed to treat involuntary abdominal spasms related to Huntington's, a hereditary neurodegenerative disease that results in motor, cognitive, and psychiatric disability, primarily due to the destruction of neurons in the brain.

SD-809 is in advanced clinical trials and has already shown a tremendous amount of potential. Other drugs in Auspex's pipeline include those used to treat rheumatoid arthritis and conditions like pulmonary fibrosis (scarring of the lungs) and obstruction of the coronary arteries.

Profit Machine No. 2

Revance Therapeutics

On Feb. 6, Revance Therapeutics, Inc. (Nasdaq: RVNC) went public with an offering price $16. Recently trading at about $36, the stock is already up 125%.

Revance isa specialty firm focused primarily on products for dermatological applications that provide an alternative to Botox injections.

As such, the company's lead product does rely on the botulinum toxin but is applied topically to reduce or eliminate facial lines like "crow's feet" and "laugh lines."

Currently in advanced clinical trials, the product is significant for patients who prefer to avoid injections. However, Revance does have a similar leading candidate, RT002, that is essentially an injectable form of compound.

Other products in Revance's pipeline include those used to treat migraine headaches, excessive and unexpected perspiration, and other facial lines. Most of these product candidates are either in early or mid-stage trials.

The company says it is addressing markets that will grow 72% from $2.5 billion in the 2012 base year to $4.3 billion in 2018. Revance also says it expects to launch three products by 2017.

Profit Machine No. 3

Cara Therapeutics

With a market cap now valued at $375 million, Cara Therapeutics Inc. (Nasdaq: CARA)began trading on Jan. 31 with an offering price of $11. After a recent correction, the stock has gains to date of about 26%. I think that makes it an even better bargain.

Cara is developing therapies to treat acute and chronic pain as well as diseases associated with inflammation. In particular, it's focused on postoperative pain.

This is a potentially huge market. Some 46 million inpatient and 53 million outpatient surgeries are performed in the United States each year that require a pain relief drug. Cara officials say research reveals that more than half of those patients complain of inadequate relief.

Its most promising therapeutic is CR845, a compound developed to specifically treat acute pain with anti-inflammatory properties. Cara is working on two forms of CR845, injectable and pill versions.

At the same time, it is also working on a compound that treats pain and swelling based on a form of cannabis (marijuana). Known as CR701, the drug has shown promise when used in rodents, but has not yet entered human trials.

Along with the other winners, Cara shows that the biotech stocks that we've looked at hold great promise for both patients and investors alike.

And with the market pullback, now is the time to take advantage...

Source : http://moneymorning.com/2014/04/25/these-long-term-profit-machines-just-went-on-sale/

Money Morning/The Money Map Report

©2014 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in